Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)
0:00
10:26
Professor Sergio Harari joins us to discuss the results of a phase 2 clinical trial evaluating activity and safety of nintedanib in people with lymphangioleiomyomatosis (LAM).
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Altri episodi di "The Lancet Respiratory Medicine in conversation with"
Non perdere nemmeno un episodio di “The Lancet Respiratory Medicine in conversation with”. Iscriviti all'app gratuita GetPodcast.